Next-generation sequencing

Next-generation sequencing (NGS) can deliver unprecedented insights, unraveling the intricacies of the genome and transcriptome in biomarker research, gene expression studies, viral epidemiology and disease surveillance, as well as comprehensive genomic profiling to identify variants implicated in cancer and other diseases. However, challenges such as workflow optimization, customization and data analysis and interpretation can hinder progress.

Uncover more biology with NGS technology

Navigate the complexity of the NGS world with ease by partnering with QIAGEN. Benefit from extensive expertise, tailored solutions and market-leading informatics so you can achieve:

• Accurate results from even the most challenging of samples
• Faster turnaround times using streamlined and optimized workflows
• Meaningful insights from complex NGS data

High-throughput genomic surveillance of emerging SARS-CoV-2 variants B.1.1.7 and B.1.351

The emergence of new, highly transmissible SARS-CoV-2 variants has elevated the need for high-throughput whole viral genome sequencing to accelerate genomic surveillance efforts. Cataloging new variants and evaluating the impact of the accumulated mutations is critical for vaccine development and effective public health measures. Explore how our high-performance, scalable NGS workflows with integrated bioinformatics facilitate accurate SARS-CoV-2 variant detection and phylogeographic tracking.

Expanding disease insights with exome sequencing

The coding portion of the genome holds tantalizing information on multiple diseases. Unlocking these details through exome sequencing can reveal powerful insights into disease-associated variants. However, coverage issues, long turnaround times and data analysis bottlenecks can diminish progress. Explore a time-saving workflow that seamlessly combines uniform exome coverage with streamlined secondary analysis, rapid variant filtering and annotation.

Accelerating human and bacterial co-expression studies with high-quality RNA-seq data

Dr. Marie Adams from the Van Andel Institute discusses how QIAseq FastSelect technology helped conquer the challenges of generating high-quality RNA-seq data for human and bacterial co-expression studies from the same RNA sample.

Increasing RNA-seq sensitivity in cancer research

Researchers from the University of Houston discuss how powerful QIAseq FastSelect rRNA removal technology transformed their research, allowing them to retrieve useful RNA-seq data from FFPE RNA.

Defending against cancer by manipulating the immune system using NGS technology

Dr. Nathalie Labarrière from the University of Nantes describes her work using QIAseq Immune Repertoire RNA Library Kits to target colon cancer and melanoma tumors in new immuno-oncology therapies.

Driving insights into pancreatic cancer risk using custom NGS panels

Dr. Fergus Couch from the Mayo Clinic discusses how QIAseq Targeted DNA Panels played a vital role in a longitudinal case-control study on the risk of pancreatic cancer.

Ensuring uniform coverage enables heterozygous mutation detection in cancer research

Dr. Egbert Schulze from the Endocrinology and Nuclear Medicine Community Practice, Heidelberg, discusses how the all-enzymatic QIAseq FX workflow enabled uniform coverage and helped him achieve reliable sequencing results in his research.